ABUS Arbutus Biopharma Corporation

2.42
+0.24  (+11%)
Previous Close 2.18
Open 2.17
Price To Book 2.69
Market Cap 140,394,296
Shares 58,014,172
Volume 769,375
Short Ratio
Av. Daily Volume 518,937

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial ongoing but no plans to continue further development.
ARB-1467, tenofovir, and pegylated interferon
Hepatitis B (HBV)
Phase 2 Cohort 4 data released September 25, 2017 with detailed data due at AASLD in October 2017.
ARB-1467
Hepatitis B (HBV)
Phase 1 trial initiation delayed - noted October 9, 2018. Decision regarding clinical development due early 2020.
AB-452
Hepatitis B
Phase 1 data due July 2019.
AB-506
Hepatitis B (HBV)
Phase 1a/b trial to be initiated to be initiated shortly - June 21, 2019.
AB-729
Hepatitis B (HBV)

Latest News

  1. Arbutus Gets Clearance to Initiate Hepatitis Study, Stock Up
  2. Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729
  3. Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
  4. Arbutus to Participate at JMP Securities Life Sciences Conference
  5. Is Arbutus Biopharma Corporation (NASDAQ:ABUS) Excessively Paying Its CEO?
  6. Arbutus to Present at Upcoming May 2019 Conferences
  7. Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
  8. Arbutus: 1Q Earnings Snapshot
  9. Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
  10. Arbutus to Report First Quarter 2019 Financial Results
  11. Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  12. 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
  13. Top Ranked Momentum Stocks to Buy for April 8th
  14. Arbutus Biopharma Corporation (NASDAQ:ABUS): Will The Growth Last?
  15. Arbutus Biopharma Corp (ABUS) Q4 2018 Earnings Conference Call Transcript
  16. Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
  17. Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update
  18. Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results
  19. Can We See Significant Insider Ownership On The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Register?
  20. Do Hedge Funds Love Arbutus Biopharma Corp (ABUS)?